Interaction between parathyroid hormone and the Charlson comorbidity index on survival of incident haemodialysis patients by L. Morrone et al.
iPTH and comorbidities in incident ESRD patients 2859
11. Moe S, Drueke TB. Management of secondary hyperparathyroidism:
the importance and the challenge of controlling parathyroid hor-
mone levels without elevating calcium, phosphorus, and calcium-
phosphorus product. Am J Nephrol 2003; 23: 369–379
12. Hammerland LG, Garrett JE, Hung BCP et al. Allosteric activation of
the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467
or NPS 568. Mol Pharmacol 1998; 53: 1083–1088
13. Nemeth EF, Steffey ME, Hammerland LG et al. Calcimimetics with
potent and selective activity on the parathyroid calcium receptor. Proc
Natl Acad Sci USA 1998; 95: 4040–4045
14. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary
hyperparathyroidism in patients receiving hemodialysis.NEngl JMed
2004; 350: 1516–1525
15. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral
calcimimetic agent for the treatment of secondary hyperparathy-
roidism in hemodialysis and peritoneal dialysis: a randomized,
double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800–
807
16. Frazao JM, Holzer H, Stummvoll HK et al. Cinacalcet
(Mimpara R©/Sensipar R©) maintains achievement of NKF-K/DOQI
treatment targets for secondary hyperparathyroidism (HPT) in pa-
tients on dialysis (Abstract). Nephrol Dial Transplant 2005; 20
(Suppl 5): SP209
17. Martin KJ, Juppner H, Sherrand DJ et al. First- and second-generation
immunometric PTH assays during treatment of hyperparathyroidism
with cinacalcet HCL. Kidney Int 2005; 68: 1236–1243
18. Messa P, Maca´rio F, Yaqoob M et al. The OPTIMA study: assessing a
new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary
hyperparathyroidism. Clin J Am Soc Nephrol 2008; 3: 36–45
19. St Peter WL, Li Q, Liu J et al. Cinacalcet use patterns and effect on lab-
oratory values and other medications in a large dialysis organization,
2004 through 2006. Clin J Am Soc Nephrol 2009; 4: 354–360
20. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI
bone metabolism and disease treatment goals with cinacalcet HCl.
Kidney Int 2005; 67: 760–771
21. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis
patients with different levels of serum calcium, phosphorus, and PTH:
the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J
Kidney Dis 2008; 52: 519–530
22. Henley D, Shatzen E, Lott F et al. Distribution and elimination of 45Ca
after oral administration of a calcimimetic in cynomolgus monkeys
under calcium loading conditions. Nephrol Dial Transplant 2007;
22(Suppl 6): 217 (abstract Sa0013)
23. Lopez I, Mendoza FJ, Aguilera-Tejero E et al. The effect of calcitriol,
paricalcitol and a calcimimetic on extraosseous calcifications in ure-
mic rats. Kidney Int 2008; 73: 300–307
Received for publication: 8.10.08; Accepted in revised form: 11.3.09
Nephrol Dial Transplant (2009) 24: 2859–2865
doi: 10.1093/ndt/gfp170
Advance Access publication 15 April 2009
Interaction between parathyroid hormone and the Charlson
comorbidity index on survival of incident haemodialysis patients
Luigi Francesco Morrone1, Sandro Mazzaferro2, Domenico Russo3, Filippo Aucella4, Mario
Cozzolino5, Maria Grazia Facchini6, Andrea Galfre`7, Fabio Malberti8, Maria Cristina Mereu9,
Maurizio Nordio10, Giovanni Pertosa11, Domenico Santoro12 and CPCP Study Investigators∗
1Renal Division, A.O. Rummo, 82100 Benevento, 2Renal Division, Universita` ‘Sapienza’, 00161 Roma, 3Renal Division, University
Federico II, 80131 Napoli, 4Renal Division, PO Lastaria, 71036 Lucera, 5Renal Division, A.O. San Paolo Polo Universitario, Milano,
6Renal Division, A.O. Sant’ Orsola Malpighi, 40138 Bologna, 7Renal Division, Dialisi Territoriale, 09100 Cagliari, 8Renal Division,
A.O. Istituti Ospitalieri, 26100 Cremona, 9Renal Division, PO Nostra Signora di Bonaria, 09025 S. Gavino Monreale, 10Renal
Division, P.O. Campo San Piero, 35100 Padova, 11Renal Division, Azienda Universitaria Ospedaliera Policlinico, 70124 Bari and
12Renal Division, Universita` degli Studi di Messina, 98128 Messina, Italy
Correspondence and offprint requests to: Luigi Francesco Morrone; E-mail: l.morrone@fastwebnet.it
∗Investigators of the CPCP (‘Comorbidity–Parathormone–Calcium–Phosphate’) study, belonging to the ‘Mineral Metabolism and
Trace Elements’ study group of the Italian Society of Nephrology, are listed in the Appendix.
Abstract
Background. Haemodialysis patients are ageing and have
with a high rate of comorbidities. The impact of this novel
clinical setting on intact parathyroid hormone (iPTH) is not
well established.
Methods. For this observational, prospective multicen-
tre cohort study, incident haemodialysis patients were re-
cruited in 40 Italian centres and followed up for a mean
period of 18 ± 6.7 months. Clinical characteristics and
biochemistry were recorded at baseline. Comorbid con-
ditions were scored by the Charlson comorbidity index
(CCI).
Results. Data of 411 patients (mean age: 66.5 ± 14.8
years; 17.3% >80 years old) were recorded. The mean
CCI was 4.17 ± 2.8. In patients with CCI >0, an in-
verse correlation was observed between CCI (excluding
age) and iPTH (P = 0.00002). Independently of CCI, pa-
tients with iPTH <150 pg/ml had 76% as high as the risk
C© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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of all-cause mortality. After multivariable adjustment, the
combination of the first tertile of iPTH with second and
third tertiles of CCI was significantly associated with all-
cause mortality (RR = 3.83,P= 0.02; RR = 3.79,P= 0.01,
respectively).
Conclusions. Incident haemodialysis patients suffer from
a high rate of clinical complications. In these patients, low
iPTH and high CCI are often associated and very likely
responsible for an adverse outcome.
Keywords: Charlson index; elderly; incident ESRD patients; intact
parathyroid hormone; survival
Introduction
In most western countries, the median age of patients start-
ing renal replacement therapy (RRT) has increased over the
last decade with a concomitant rise in comorbidities and
with diabetes as the leading cause of renal failure [1–5].
Other frequent comorbidities are cancer (11%), coronary,
cerebral and/or peripheral vascular disease (61%) [6].
Comorbidities in ageing patients represent an emerging
problem for nephrologists, and these make the manage-
ment of patients in RRT even more difficult despite the
progress in dialysis techniques [6,7]. Therefore, greater at-
tention and specific research probably should be devoted
to the above-mentioned comorbidities, going beyond the
traditional role as a statistical adjustment tool in survival
studies on patients with chronic kidney disease (CKD).
For instance, the impact of comorbidities on some CKD
complications such as the CKD-mineral bone disorder is
unknown.
Comorbidities can be assessed in several ways. In the
general population, the Charlson comorbidity index (CCI)
is commonly used. In its original structure as well as in
ensuing adaptations, the CCI is considered as a valid and
easy to use method for assessing comorbidities and predict-
ing survival also in incident patients with end-stage renal
disease (ESRD) [8–12].
The present study aimed at investigating the relationship
between comorbidities and intact parathyroid hormone as
well as the impact of their interaction on survival in a cohort
of incident haemodialysis patients.
Subjects and methods
The present observational cohort study was performed in 411 incident
haemodialysis patients who started treatment between 13 January 2005
and 4 September 2007. Data were collected from 40 Italian renal units.
The study has been exclusively managed by nephrologists belonging to
the ‘Mineral Metabolism and Trace Elements study group’ of the Italian
Society of Nephrology. The study was completely independent and did
not receive support from any pharmaceutical or medical company.
The STROBE recommendations for observational studies (http://www.
strobe-statement.org) were taken into account.
Inclusion criteria
Consecutive patients (age >21 years) who started RRT in each partici-
pating centre during the 1-year enrolment period were allowed to enter
the study. A further inclusion criterion was adequacy of dialysis dose ac-
cording to K/DOQI guidelines (spKt/V >1.2, assessed using pre-dialysis
and post-dialysis blood urea nitrogen sampling). Exclusion criteria were
as follows: previous kidney transplant, switch from peritoneal dialysis and
spKt/V ≤1.2 in two consecutive monthly measurements. During the 1-
year enrolment period, 500 patients started RRT. The median number of
patients for each centre was 9 (range 2–59). From the initial cohort, 15
patients did not fit inclusion criteria and 24 did not have complete data.
Patients on peritoneal dialysis (n = 38) and those on haemodialysis on
calcium in dialysate different from 1.50 mmol/l (n = 12) were excluded.
Thus, 411 patients were recruited.
Data collection
Baseline data were as follows: patient identifying code, birth date, gen-
der, underlying kidney disease, dialysis start date, duration of pre-dialysis
follow-up, smoking habit, co-morbid conditions, ability to walk with-
out assistance, systolic and diastolic blood pressure, anti-hypertensive
drugs, treatment and dosages of vitamin D receptor activators (VDRA),
calcimimetic and phosphate-binding drugs. In addition, the following
laboratory data were recorded: serum calcium, phosphate, albumin and
haemoglobin (determined within 1 month from the beginning of dialy-
sis), concentration of serum intact parathyroid hormone (iPTH) (assayed
within the first 2 months of dialysis using second generation methods) and
C-reactive protein (C-rp) (assayed within the first 3 months of dialysis).
The blood samples were collected using uniform techniques before the
start of the first dialysis session of the week and were sent to the lab-
oratory within 2 h, with the iPTH sample on ice. Serum total calcium
was corrected for albuminaemia according to the formula: albumin − cor-
rected calcium = measured calcium + (4.0 − serum albumin in g/dl) ×
0.8) [13].
Patients with a positive history of hyperglycaemia and/or on chronic
treatment with insulin or anti-diabetic drugs were regarded as diabetic.
In accordance with the JNC-7 guidelines, hypertension was defined as
systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure
(DBP) ≥90 mmHg [14]. Patients with systolic pressure ≤90 mmHg were
arbitrarily recorded as hypotensive. Patients with a pre-dialysis follow-up
<4 months were labelled as ‘late referrals’ to the nephrology service [15].
The presence and degree of comorbid conditions were assessed using
the CCI at the beginning of dialysis [8]. The CCI includes age (weight 1
for every 10 years starting from 40 years of age) and contains 17 categories
of comorbidities including congestive heart failure (weight 1), myocardial
infarction (weight 1), chronic pulmonary disease (weight 1), cerebrovas-
cular disease (weight 1), haemiplegia or paraplegia (weight 2), dementia
(weight 1), diabetes (weight 1), diabetes with complication (weight 2),
malignancy (weight 2), metastatic solid tumour (weight 6), mild liver dis-
ease (weight 1), moderate or severe liver disease (weight 3), peptic ulcer
disease (weight 1), peripheral vascular disease (weight 1), rheumatologic
disease (weight 1), renal disease (weight 2) and AIDS (weight 6). In this
study, the CCI score for the presence of kidney disease was not taken into
account being all patients were on RRT.
The following cardiovascular events were recorded: stroke or transient
ischaemic attack, angina pectoris or acute myocardial infarction, con-
gestive heart failure, haemodynamically significant tachyarrhythmias or
bradyarrythmias, and dissecting aneurysm of the aorta.
Death due to one of the above events was recorded as death from cardio-
vascular causes. Other deaths were considered not due to cardiovascular
causes.
The diagnosis of cardiovascular events was based on medical records
obtained from participating centres and reviewed by the principal investi-
gator of the study (L.F.M.).
Statistics
All data are presented as proportions of the patient population, mean ±
standard deviation or median and range, as appropriate. Differences be-
tween groups were evaluated using the Kruskal–Wallis test, one-way
ANOVA or χ2 analysis, where necessary.
Due to the multicentre nature of the study, iPTH levels were assayed in
different laboratories and with different commercial kits. Accordingly, we
have applied a hierarchical multilevel regression approach that enabled us
to take into account the centre and method effects. The multilevel model
used included random intercepts and fixed slopes. The assumption is that
the effects are fixed for centres and methods, whereas the mean effect of
each hospital is allowed to vary [16]. A likelihood ratio (LR) test was used
to evaluate the suitability of the single level versus multilevel regression
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Table 1. Patient characteristics
Number of patients 411
Male/female ratio 1.66
Age over 65 years, n (%) 235 (57.2)
Age over 80 years, n (%) 71 (17.3)
Diabetes, n (%) 96 (23.4)
Arterial hypertension, n (%) 242 (58.9)
Late referral, n (%) 144 (35.0)
Autonomous walking impairment, n (%) 84 (20.4)
Aetiology of ESRD, n (%)
Diabetic nephrophathy 88 (21)
Nephroangiosclerosis 82 (20)
Glomerulonephritis 45(11)
Interstitial nephritis 41 (10)
Vasculitis 8 (2)
Others and unknown 147 (36)
Comorbidities, n (%)
CCI above 0 372 (91)
CCI above 1 343 (83)
Age (decades over 4th) 353 (86)
Diabetes with complications 96 (23)
Cardiovascular disease 53 (13)
Chronic pulmonary disease 38 (9)
Neurologic disease 21 (5)
Rheumatologic disease 19 (5)
Liver disease 19 (5)
Neoplasms 11 (3)
Peptic ulcer 7 (2)
The multilevel procedure was statistically able to exclude any confounding
effect of centres and assay methods on iPTH variable, when it was included
in a regression model together with the CCI regressor.
Spearman’s regression analysis was used to evaluate the CCI values
with respect to age and iPTH. Multiple regression models were applied
to examine whether the CCI was related to the logarithm of iPTH, after
adjustment for several covariates. Survival curves were derived with the
Kaplan–Meier method using the log-rank test to evaluate the differences
between the curves. The Cox procedure was used to model death as a func-
tion of serum iPTH levels alone or in combination with the CCI score,
both expressed as tertiles. Therefore, the Cox model for all-cause survival
was adjusted for age, gender, diabetes, arterial hypertension, late refer-
ral, vitamin D administration, circulating levels of haemoglobin, albumin,
calcium and phosphate. Estimated relative risk (RR) and their 90% confi-
dence limits were calculated using estimated regression coefficients and
their standard errors. To evaluate potential interactions among age, iPTH
and CCI, a multivariate regression model was built where dependent vari-
able was all-cause mortality and independent variables were iPTH, age,
CCI and their interaction terms. Interaction (product) terms were given
by iPTH × CCI, iPTH × age and CCI × age. In this model, age was
excluded from the CCI and analysis was restricted only to patients with
comorbidities.
A two-sided P-value <0.05 was considered statistically significant.
Statistical procedures were performed using the statistical packages
NCSS 2007, PASS 2005 (NCSS, Kaysville, UT, USA) and STATA 10
(Stata Corp., College Station, TX, USA).
Results
Study population
A total of 260 males and 151 females (mean age: 66.5 ±
14.8 years) were enrolled. The patient characteristics at the
start of RRT are presented in Table 1. Most patients were
elderly and had multiple co-morbidities. A few diabetic pa-
tients did not have diabetic nephropathy (2%), but a renal
biopsy was performed only in 12% of all patients. Under-
lying kidney diseases and most frequent comorbidities are
Fig. 1. Distribution of the CCI.
also reported in Table 1. Figure 1 shows the distribution of
the CCI score in the whole cohort.
Baseline clinico-laboratory characteristics according to
iPTH levels
Tables 2 and 3 show the clinico-laboratory characteristics of
patients at the dialysis initiation according to iPTH. Patients
with low-to-normal iPTH levels had a significantly higher
rate of the CCI (excluding age) (P = 0.01) and diabetes
(P = 0.03). Patients with low iPTH displayed the highest
frequency of late referral (P = 0.005), high serum calcium
(P = 0.01) and low serum phosphate (P = 0.02). Patients
with iPTH >300 pg/ml had more frequently low serum
calcium levels (P = 0.001), and they were more frequently
treated with active forms of vitamin D (P= 0.0003). Among
patients with iPTH > 300 pg/ml, 25% (9% of the entire
cohort) had iPTH >600 pg/ml.
Correlation between iPTH levels and CCI
Non-significant correlation between iPTH and CCI was
observed in the entire cohort. In contrast, the correla-
tion became significant when data of patients without co-
morbidities were not taken into account (rho = −0.12, P =
0.02). Of note, the statistical significance increased (rho =
−0.25, P = 0.00001) when age was excluded from the
CCI. The inverse correlation persisted (rho = −0.31, P =
0.001) when analysis was repeated in the subgroup of pa-
tients with comorbidities but younger than 65 years old.
Finally, the inverse correlation was confirmed in a multiple
regression model adjusted for serum calcium and phosphate
and active vitamin D administration; the highest correlation
(beta = −0.20, P = 0.0004) was observed in patients with
a CCI >0 when age was excluded from CCI calculation;
the significance remained high (beta = −0.16, P = 0.004)
when diabetes and serum albumin were added as adjustment
covariates.
Survival analysis
The mean follow-up was of 18.8 ± 6.7 months. During
the observational period, 77 out of 411 patients (18.8%)
died: 31 (40.3%) and 46 (59.7%) because of cardiovascular
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Table 2. Characteristics of incident chronic haemodialysis patients subdivided according to circulating iPTH levels
iPTH < 150 pg/ml iPTH 150–300 pg/ml iPTH > 300 pg/ml P-value
Patients (%) 132 (32.1) 126 (30.7) 153 (37.2)
Male gender (%) 62.9 69.0 58.8 N.S.
Age: median (range) 68.0 (22–90) 70.5 (23–92) 69.0 (21–96) N.S
CCI: median (range) 4.0 (0–14) 5.0 (0–13) 4.0 (0–15) N.S.
CCI excluding age: median (range) 2 (0–10) 2 (0–10) 1 (0–11) 0.01
Diabetic patients (%) 26.5 28.6 16.3 0.03
Hypertensive patients (%) 53.8 56.5 65.5 N.S.
Hypotensive patients (%) 0.8 0.9 1.4 N.S.
Late referred patients (%) 45.5 33.3 27.5 0.005
Cigarette smoking (%) 29.7 24.6 20.5 N.S.
Haemoglobin < 11 g/dl (%) 78.6 75.4 71.9 N.S.
C-rp = 3.11 mg/dl (%) 40.2 34.0 32.4 N.S.
Serum albumin = 3.2 g/dl (%) 34.4 22.4 23.9 N.S.
Corrected calcium > 9.5 mg/dl (%) 44.8 38.3 27.8 0.01
Corrected calcium < 8.4 mg/dl (%) 6.4 13.9 21.8 0.001
Phosphorus > 5.5 mg/dl (%) 32.1 42.9 43.8 N.S.
Phosphorus < 3.5 mg/dl (%) 17.6 7.9 9.2 0.02
All active vitamin D administration (%) 25.0 35.7 48.0 0.0003
Oral calcitriol administration (%) 22.7 29.4 27.7 N.S.
Phosphate binders administration (%) 67.4 76.0 73.9 N.S.
Calcium salts administration (%) 40.2 44.0 52.9 N.S.
C-rp 3.11 mg/dl= third tertile; serum albumin 3.2 g/dl= first quartile; haemoglobin, iPTH, calcium and phosphate concentrations are categorized
according to K/DOQI recommendations for stage 5 CKD.
Table 3. Clinical and laboratory characteristics (mean ± standard deviation) of incident chronic haemodialysis patients subdivided according to
circulating iPTH levels
iPTH < 150 pg/ml iPTH 150–300 pg/ml iPTH > 300 pg/ml
(mean ± SD) (mean ± SD) (mean ± SD) P-value
Age (years) 66.1 ± 13.4 66.5 ± 15.9 66.8 ± 15.0 N.S.
Systolic blood pressure (mmHg) 144 ± 22 144 ± 23 142 ± 24 N.S.
Diastolic blood pressure (mmHg) 77 ± 11 80 ± 12 78 ± 12 N.S.
Corrected calcium (mg/dl) 9.43 ± 0.85 9.27 ± 0.80 9.06 ± 0.86 0.003
Phosphorus (mg/dl) 4.91 ± 1.53 5.32 ± 1.62 5.36 ± 1.46 0.01
Haemoglobin (g/dl) 9.72 ± 1.39 9.96 ± 1.53 10.1 ± 1.39 N.S.
C-rp (mg/dl) 4.80 ± 6.81 3.95 ± 6.27 3.64 ± 6.40 N.S.
Serum albumin (g/dl) 3.38 ± 0.57 3.55 ± 0.52 3.60 ± 0.54 0.02
CCI-adjusted (CCI as continuous variable) relative risk of
death for all-cause, non-cardiovascular and cardiovascular
causes, grouping patients on iPTH concentration and as-
suming iPTH = 150–300 pg/ml as reference. The relative
risk of death increased in patients with iPTH <150 pg/ml,
but reached the statistical significance only for all-cause
mortality.
The Kaplan–Meier survival curves for all-cause mortal-
ity (Figure 3) point out a significantly (P< 0.00001) worse
survival for patients with a combination of highest tertile
of CCI and lowest one of iPTH.
The results of multivariable-adjusted Cox analysis to
test the effect on survival of several combinations be-
tween tertiles of CCI and tertiles of iPTH are shown in
Figure 4. The worst combination for all-cause mortality
was second and third tertiles of CCI with first tertile of
iPTH (RR = 3.83, P = 0.02; RR = 3.79, P = 0.01,
respectively). Finally, the interaction between iPTH and
CCI on patient survival was underlined in the interaction
test where the interaction term iPTH × CCI was signifi-
cantly associated with all-cause mortality (beta = −0.20,
P < 0.05).
Fig. 2. CCI-adjusted risk of death and 95% confidence limits (C.L.) in
patients with iPTH outside the K/DOQI target range, considering patients
with PTH in a range as the reference group.
Discussion
The increased serum concentration of phosphate and cal-
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Fig. 3. Kaplan–Meier survival curves for all-cause mortality in patients
subdivided according to combinations between tertiles of the CCI (exclud-
ing age) and tertiles of iPTH.
RRT [17–20]. PTH has been often associated with higher
mortality rate [17–20]. Instead, survival analyses have
yielded conflicting results on the effects of low PTH
[17–23].
The incident dialysis population represents an interest-
ing cohort to identify potential causes of high mortality
observed within the first year of dialysis. In this popula-
tion, both high and low PTH were correlated with a signif-
icant reduction in the quality of life, while low PTH had no
detrimental effect on survival [20,24].
In the present study, we have evaluated the data of 411 in-
cident haemodialysis patients and found a very high overall
rate of clinical complications.
Late referral and low concentration of serum albumin
were frequently found in patients with low iPTH; the latter
finding may indicate sub-optimal clinical care of patients
in pre-dialysis stages and consequent malnutrition.
An inverse relationship between the CCI and iPTH was
observed in comorbid patients, and it was independent of di-
abetes, active vitamin D administration and concentrations
of serum calcium, phosphate and albumin. Potential links
between the CCI and iPTH may be the limitation in skeletal
mobilization and/or the malnutrition frequently observed in
patients with high-grade comorbidities. In fact, the limita-
tion in skeletal mobilization may increase serum calcium
with consequent reduced secretion of iPTH. Despite the fact
that high serum calcium and low serum albumin were more
frequently found in our patients with low iPTH, the inverse
association between the CCI and iPTH was independent of
both variables. However, it is difficult to deduce from PTH
levels the metabolic state of bone. Not all patients with
low iPTH have reduced bone turnover; at the same time,
patients with high iPTH do not have increased turnover
[25].
The lack of an increased risk of death in patients with
iPTH > 300 pg/ml should be viewed with caution because
only 9% of the entire cohort had iPTH > 600 pg/ml which
has been associated with an increased mortality in prevalent
dialysis patients [18]. The weak statistical association be-
tween low iPTH and CCI-adjusted risk of death and the
presence of inverse correlation between iPTH and CCI
prompted us to look for more distinctive interactions be-
tween both factors and evaluate the impact of their combi-
nations on all-cause mortality. The attained data highlighted
the hazardousness of the combinations of lowest tertile of
iPTH and highest tertiles of the CCI. Remarkably, the detri-
mental effect of high CCI on survival was mostly evident
in patients with low iPTH. However, a trend between rising
CCI and risk of death was observed also in patients with
high tertiles of iPTH; the lack of statistical significance
may be due once more to the low percentage of patients
with very high iPTH.
From the standpoint of the clinical implications, more
attention should be devoted to all interventions aiming at
attenuating the high mortality risk present in haemodialysis
Fig. 4. Multivariable-adjusted risk of all-cause death and 95% confidence limits (C.L.) in patients subdivided according to combinations between
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patients with low iPTH and high CCI. The first step is a bet-
ter management of the alterations in mineral metabolism,
an aspect that showed some inadequacies. In fact, at the
start of RRT vitamin D and calcium salts were still admin-
istered to 25.0% and to 40.2% of our patients with a low
concentration of serum iPTH, respectively. Despite obser-
vational studies which have shown a beneficial effect of
vitamin D compounds on patients’ survival, in our patients
the detrimental effect of low iPTH and high CCI on survival
was independent of vitamin D administration, at least at the
start of RRT.
The present study has some limitations. iPTH was ob-
tained at several renal units with different second generation
assay methods. Nonetheless, the regression model multi-
level analyses did not show any significant influence of the
nested levels method and centre. Survival analysis based
on a single baseline value of iPTH may be questioned, but
this is the case of many other studies. Furthermore, the
mortality risk was not different when iPTH was analysed
at baseline, as a standard time-dependent covariate and as
a cumulative time-dependent covariate [24]. Data analysis
took into account only drugs administered at the start of
RRT but not the variations occurring during the observa-
tion period. In some patients the follow-up might appear
too short, but only 5% and 1% of patients had censoring
time shorter than 12 and 6 months, respectively. Of note,
these patients were free from events; their influence on the
outcome analysis may be regarded as negligible.
In conclusion, incident haemodialysis patients suffer
from a high rate of clinical complications. In these pa-
tients, low iPTH and high CCI are often associated and
their interaction affects survival negatively.
Conflict of interest statement. None declared.
Appendix: investigators of the CPCP
(Comorbidity–Parathormone–Calcium–
Phosphate) study
Paolo Altieri Azienda Ospedaliera Brotzu—CAGLIARI;
Enzo Ancarani, Ospedale Belcolle ASL—VITERBO;
Fabrizio Assini, Ambulatorio Emodialisi San Pio—
AFRAGOLA (NA); Alice Atzeni, Unita` Ospedaliera
Dialisi Territoriale—CAGLIARI; Maria Auricchio, Pre-
sidio Ospedaliero San Leonardo—CASTELLAMARE
DI STABIA (NA); Guido Bellinghieri, Universita` degli
Studi di Messina—MESSINA; Piergiorgio Bolasco, Unita`
Ospedaliera Dialisi Territoriale—CAGLIARI; Francesco
Bondatti, Ospedale S. Benedetto—ALATRI (FR);
Diego Brancaccio, Azienda Ospedaliera San Paolo Polo
Universitario—MILANO; Maurizio Brigante, Azienda Os-
pedaliera Cardarelli—CAMPOBASSO; Maria Capuano,
Ospedale dei Pellegrini—NAPOLI; Maria Cesarano,
Presidio Ospedaliero San Leonardo—CASTELLAMARE
DI STABIA (NA); Stefano Chimienti, Ospedale Civile
Giannuzzi—MANDURIA (TA); Pasquale Coratelli,
Azienda Universita` Ospedaliera Policlinico—BARI;
Roberto Corciulo, Azienda Universita` Ospedaliera
Policlinico—BARI; Alex Corsaro, Azienda Ospedaliera
Istituti Ospitalieri—VERONA; Olga Credentino, Azienda
Ospedaliera Cardarelli—NAPOLI; Ludovica D’apice,
Azienda Ospedaliera S. Sebastiano—CASERTA;
Filomena D’elia, Presidio Ospedaliero—MOLFETTA
(BA); Teresa Dipalma, Azienda Ospedaliera Istituti
Ospitalieri—VERONA; Biagio Raffaele Di Iorio, Ospedale
Landolfi—SOLOFRA (AV); Silvio Di Stante, Azienda Os-
pedaliera Cardarelli—CAMPOBASSO; Raffaela Esposito,
Ambulatorio Emodialisi San Biagio—CASORIA (NA);
Riziero Fini, Ospedale S. Benedetto—ALATRI (FR);
Antonio Galise, Ambulatorio Emodialisi C.M.M.—CAVA
DEI TIRRENI (NA); Loreto Gesualdo, Azienda Univer-
sita` Ospedaliera Ospedali Riuniti—FOGGIA; Antonio
Gesuete, IRCCS Casa Sollievo della Sofferenza—S.
GIOVANNI ROTONDO (FG); Pasqua Giangregorio,
Presidio Ospedaliero—MOLFETTA (BA); Michele Gian-
nattasio, Ospedale S.Maria degli Angeli—PUTIGNANO
(BA); Giuseppina Giannetto, Azienda Ospedaliera
Gravina—CALTAGIRONE (CT); Francesco Godino,
Presidio Ospedaliero SS Annunziata—TARANTO; Emilio
Iele, Azienda Ospedaliera Rummo—BENEVENTO;
Maria Ktena, Azienda Universita` Ospedaliera Ospedali
Riuniti—FOGGIA; Graziella Leotta, Azienda Ospedaliera
Gravina—CALTAGIRONE (CT); Cosimo Lodeserto, Pre-
sidio Ospedaliero SS Annunziata—TARANTO; Antonio
Lupo, Azienda Ospedaliera Istituti Ospitalieri—VERONA;
Vilma Martella, Azienda Universita` Ospedaliera
Policlinico—BARI; Carlo Massimetti, Ospedale Bel-
colle ASL—VITERBO; Mario Migliorati, Ambulatorio
Emodialisi San Giorgio—TORRE DEL GRECO (NA);
Fernanda Misceo, Centro di Emodialisi New Dial—BARI;
Nicola Mongelli, Centro Dialisi Ambulatoriale
C.B.H.—BISCEGLIE (BA); Ilaria Napoletano, Ospedale
San Giovanni Decollato Androsilla—CIVITA CASTEL-
LANA (VT); Donato Paoletti, Presidio Ospedaliero
Lastaria—LUCERA (FG); Sergio Papagni, Centro Dialisi
Ambulatoriale C.B.H.—BISCEGLIE (BA); Giovanni
Maria Passaghe, Presidio Ospedaliero Dettori—TEMPIO
PAUSANIA (SS); Silvia Porreca, Azienda Universita`
Ospedaliera Policlinico—BARI; Paolo Rampa, Os-
pedale Civile Spirito Santo—PESCARA; Pietro Ravani,
Azienda Ospedaliera Istituti Ospitalieri—CREMONA;
Paolo Riveruzzi, Ospedale San Giovanni Decol-
lato Androsilla—CIVITA CASTELLANA (VT);
Roberto Russo, Azienda Universita` Ospedaliera
Policlinico—BARI; Antonio Santoro, Policlinico Sant’
Orsola Malpighi—BOLOGNA; Antonio Sarti, Presidio
Ospedaliero—SCAFATI (SA); Caterina Saviano, Azienda
Ospedaliera S. Sebastiano—CASERTA; Vincenzo Savica,
Universita` degli Studi di Messina—MESSINA; Antonio
Savino, Ambulatorio Emodialisi Capodichino—NAPOLI;
Francesco Paolo Schena, Azienda Universita` Ospedaliera
Policlinico—BARI; Palmira Schiavone, AUSL BR/1
Presidio Ospedaliero "A. Perrino"—BRINDISI; Carmine
Stallone, IRCCS Casa Sollievo della Sofferenza—S. GIO-
VANNI ROTONDO (FG); Davide Stellato, Azienda Os-
pedaliera Rummo—BENEVENTO; Paolo Strippoli, AUSL
BR/1 Presidio Ospedaliero "A. Perrino"—BRINDISI;
Vincenzo Tedesco, Presidio Ospedaliero—SCAFATI
(SA); Giuseppe Tomasino, Ambulatorio Emodialisi
San Giorgio—TORRE DEL GRECO (NA); Serena







niversità degli Studi di M
ilano user on 01 O
ctober 2019
iPTH and comorbidities in incident ESRD patients 2865
TIRRENI (NA); Sergio Trevico, Ambulatorio Emodialisi
SODAV—AVERSA (NA); Luigi Tufano, Azienda Os-
pedaliera Cardarelli—NAPOLI; Enrico Valvo, Azienda
Ospedaliera Istituti Ospitalieri—VERONA; Patrizia
Veniero, Ospedale dei Pellegrini—NAPOLI; Luigi Ver-
naglione, Ospedale Civile Giannuzzi—MANDURIA (TA);
Pierfelice Zazzera, Centro di Emodialisi New Dial—BARI.
References
1. Farrington K, Rao R, Gilg J et al. New adult patients starting renal
replacement therapy in the UK in 2005 (Chapter 3). Nephrol Dial
Transplant 2007; 22(Suppl 7): vii; 11–29
2. Misra M. Dialysis in the elderly. Blood Purif 2008; 26: 41–44
3. Foley RN, Collins AJ. End-stage renal disease in the United States: an
update from the United States Renal Data System. J Am Soc Nephrol
2007; 18: 2644–2648
4. Tomson C, Udayaraj U, Gilg J et al. Comorbidities in UK patients
at the start of renal replacement therapy (Chapter 6). Nephrol Dial
Transplant 2007; 22(Suppl 7): vii;58–68
5. Cruz JM, Piera L, Bragg-Gresham JL et al. Results of the international
hemodialysis study DOPPS in Spain and Europe.Nefrologia 2003; 23:
437–443
6. Stel VS, van Dijk PC, van Manen JG et al. Prevalence of co-morbidity
in different European RRT populations and its effect on access
to renal transplantation. Nephrol Dial Transplant 2005; 20: 2803–
2811
7. Khan IH. Comorbidity: the major challenge for survival and qual-
ity of life in end-stage renal disease. Nephrol Dial Transplant 1998;
13(Suppl 1): 76–79
8. Charlson ME, Pompei P, Ales KL et al. A new method of classifying
prognostic comorbidities in longitudinal studies: development and
validation. J Chronic Dis 1987; 40: 373–383
9. Hemmelgarn BR, Manns BJ, Quan H et al. Adapting the Charlson
comorbidity index for use in patients with ESRD. Am J Kidney Dis
2003; 42: 125–132
10. Fried L, Bernardini J, Piraino B. Charlson comorbidity index as a
predictor of outcomes in incident peritoneal dialysis patients. Am J
Kidney Dis 2001; 37: 337–342
11. Di Iorio B, Cillo N, Cirillo M et al. Charlson comorbidity index is a
predictor of outcomes in incident hemodialysis patients and correlates
with phase angle and hospitalization. Int J Artif Organs 2004; 27: 330–
336
12. Miskulin DC, Martin AA, Brown R et al. Predicting 1 year mortality in
an outpatient hemodialysis population: a comparison of comorbidity
instruments. Nephrol Dial Transplant 2004; 19: 413–420
13. Rustad P, Felding P, Franzson L et al. The Nordic reference inter-
val project 2000: recommended reference intervals for 25 common
biochemical properties. Scan J Clin Lab Invest 2004; 64: 271–284
14. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of
the Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;
289: 2560–2572
15. Kinchen KS, Sadler J, Fink N et al. The timing of specialist evaluation
in chronic kidney disease and mortality. Ann Intern Med 2002; 137:
479–486
16. Greenland S. Principles of multilevel modelling. Int J Epidemiol 2000;
29: 158–167
17. Young EW, Albert JM, Satayathum S et al. Predictors and conse-
quences of altered mineral metabolism: the Dialysis Outcomes and
Practice Patterns Study. Kidney Int 2005; 67: 1179–1187
18. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mor-
tality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol
2004; 15: 2208–2218
19. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability
of time-varying indicators of bone disease in maintenance hemodial-
ysis patients. Kidney Int 2006; 70: 771–780
20. Melamed ML, Eustace JA, Plantinga L et al. Changes in serum
calcium, phosphate, and PTH and the risk of death in incident
dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351–
357
21. Avram MM, Mittman N, Myint MM et al. Importance of low serum
intact parathyroid hormone as a predictor of mortality in hemodialysis
and peritoneal dialysis patients: 14 years of prospective observation.
Am J Kidney Dis 2001; 38: 1351–1357
22. Bonne JF, Shahapuni I, Massy Z et al. Letter on the relation between
serum Ca, PO4, and PTH with mortality in dialysis patients. Kidney
Int 2007; 71: 178
23. Wald R, Sarnak MJ, Tighiouart H et al. Disordered mineral
metabolism in hemodialysis patients: an analysis of cumulative ef-
fects in the Hemodialysis (HEMO) Study. Am J Kidney Dis 2008; 52:
531–540
24. Johansen KL, Chertow GM. Chronic kidney disease mineral bone
disorder and health-related quality of life among incident end-stage
renal-disease patients. J Ren Nutr 2007; 17: 305–313
25. Barreto FC, Barreto DV, Moyse´s RM et al. K/DOQI-recommended in-
tact PTH levels do not prevent low-turnover bone disease in hemodial-
ysis patients. Kidney Int 73: 771–777







niversità degli Studi di M
ilano user on 01 O
ctober 2019
